Catalyst and Momentum Trials Data Fuels Optimism for Corcept Therapeutics (CORT)

Article excerpt

Corcept Therapeutics surged on clinical trial data showing promise for its cortisol-targeting drugs. The Catalyst and Momentum trials, testing the company's compounds in patients with Cushing's syndrome and severe depression, delivered results that analysts say could expand the addressable market beyond current estimates. Corcept's stock gained momentum as investors digested the implications for both rare-disease and psychiatric-use cases. The trials mark a potential inflection point for a company historically focused on a smaller patient population, with the depression indication potentially opening a much larger commercial opportunity.